Paxman AB (PXMBF)
OTHER OTC:PXMBF
PXMBF Stock Chart & Stats
$3.50
$0.00(0.00%)
At close: 4:00 PM EDT
$3.50
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3.50 - $3.50
Previous CloseN/A
Volume298.00
Average Volume (3M)0.00
Market Cap
$116.99M
Enterprise Value$995.33M
Total Cash (Recent Filing)$120.83M
Total Debt (Recent Filing)$13.01M
Price to Earnings (P/E)―
Beta0.00
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding23,273,417
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.05
Price to Sales (P/S)3.95
P/FCF Ratio-145.60
Enterprise Value/Market Cap8.51
Enterprise Value/Revenue3.18
Enterprise Value/Gross Profit6.65
Enterprise Value/Ebitda34.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.2
Revenue Forecast (FY)$50.82M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet (low Leverage, Rising Equity)A conservative capital structure with very low debt and materially larger equity provides financial flexibility to fund installations, absorb short-term shocks, and invest in geographic or commercial expansion. This resilience supports stability across the next 2–6 months and reduces solvency risk during product rollouts.
Sustained Revenue GrowthContinued top-line growth indicates persistent demand for scalp-cooling solutions and increasing installed base. Growing revenue underpins recurring consumable and service sales, enabling scale benefits and supporting longer-term revenue visibility as clinics adopt or expand programs over multiple quarters.
Recurring, Service-backed Business ModelA mix of system sales/leases plus recurring consumables and service creates predictable, annuity-like revenue from installed units. This installed-base-driven model enhances customer stickiness and provides durable revenue streams and cross-sell opportunities over multiple treatment cycles and quarters.
Bears Say
Severe Margin Deterioration In 2025A dramatic collapse in gross margin signals structural cost, pricing, or mix issues that materially weaken core profitability. Such a shift erodes the company’s ability to cover fixed costs and fund operations from product sales, making earnings recovery and sustainable margins a multi-quarter challenge.
Inconsistent And Negative Free Cash FlowRepeated negative free cash flow and volatile operating cash generation constrain internal funding for inventory, service deployments, and capex. This inconsistency raises reliance on external financing or equity, limiting financial flexibility and potentially slowing commercial expansion over the medium term.
Profitability/return Metrics WeakenedA negative ROE and sharply falling EPS reflect deteriorating returns on capital and operational efficiency. Persistent weakness in profitability reduces shareholder return potential and may force management to prioritize cash preservation or restructuring, impacting investment in growth initiatives over coming quarters.
Paxman AB News
PXMBF FAQ
What was Paxman AB’s price range in the past 12 months?
Paxman AB lowest stock price was $3.50 and its highest was $3.50 in the past 12 months.
What is Paxman AB’s market cap?
Paxman AB’s market cap is $116.99M.
When is Paxman AB’s upcoming earnings report date?
Paxman AB’s upcoming earnings report date is May 27, 2026 which is in 61 days.
How were Paxman AB’s earnings last quarter?
Paxman AB released its earnings results on Feb 27, 2026. The company reported -$0.042 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.042.
Is Paxman AB overvalued?
According to Wall Street analysts Paxman AB’s price is currently Overvalued.
Does Paxman AB pay dividends?
Paxman AB does not currently pay dividends.
What is Paxman AB’s EPS estimate?
Paxman AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paxman AB have?
Paxman AB has 23,273,417 shares outstanding.
What happened to Paxman AB’s price movement after its last earnings report?
Paxman AB reported an EPS of -$0.042 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Paxman AB?
Currently, no hedge funds are holding shares in PXMBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Paxman AB
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Central America. It serves various cancer centers and hospitals. The comapny has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. Paxman AB (publ) was founded in 1996 and is based in Karlshamn, Sweden.
PXMBF Earnings Call
Q4 2026
0:00 / 0:00